Time to overall and complete hematologic response.

Cumulative time to onset of hematologic response (HR; comprising complete hematologic response, marrow response, and return to chronic phase), and time to onset of complete hematologic response (CHR) for patients who started therapy with daily imatinib doses of 400 mg (n = 62) or 600 mg (n = 119).